JPMorgan Chase & Co. Has $38.46 Million Holdings in CRISPR Therapeutics AG $CRSP

JPMorgan Chase & Co. lifted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 98.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 593,416 shares of the company’s stock after acquiring an additional 294,222 shares during the period. JPMorgan Chase & Co. owned approximately 0.62% of CRISPR Therapeutics worth $38,459,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in CRSP. Mirae Asset Global Investments Co. Ltd. lifted its position in CRISPR Therapeutics by 5.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after acquiring an additional 180 shares in the last quarter. Cerity Partners LLC lifted its holdings in shares of CRISPR Therapeutics by 3.0% in the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after purchasing an additional 190 shares in the last quarter. Peapack Gladstone Financial Corp lifted its holdings in shares of CRISPR Therapeutics by 3.0% in the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock valued at $339,000 after purchasing an additional 200 shares in the last quarter. Optiver Holding B.V. lifted its holdings in shares of CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after purchasing an additional 210 shares in the last quarter. Finally, Ipswich Investment Management Co. Inc. boosted its position in shares of CRISPR Therapeutics by 0.9% during the third quarter. Ipswich Investment Management Co. Inc. now owns 25,198 shares of the company’s stock worth $1,633,000 after buying an additional 230 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $46.24 on Friday. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $78.48. The company has a market cap of $4.44 billion, a P/E ratio of -7.09 and a beta of 1.72. The stock’s 50-day simple moving average is $53.26 and its 200 day simple moving average is $57.09.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The business’s revenue for the quarter was down 97.8% on a year-over-year basis. During the same period last year, the company posted ($1.01) earnings per share. As a group, equities analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CASGEVY commercial momentum — Patient starts for CASGEVY nearly tripled year‑over‑year and CRISPR plans a H1 2026 pediatric label filing, supporting revenue growth potential and commercial credibility. CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty
• Positive Sentiment: Clinical validation for CTX310 — Early CTX310 data were published in the New England Journal of Medicine and the program is moving into Phase 1b, adding clinical proof‑of‑concept for a key cardiovascular asset. CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty
• Neutral Sentiment: $550M convertible note — The company raised US$550M via 1.7308% convertible senior notes due 2031, which materially boosts cash runway to fund commercialization and trials but introduces potential future dilution if converted. How Investors May Respond To CRISPR Therapeutics (CRSP) $550 Million Convertible Note Boost To Cash Reserves
• Neutral Sentiment: Analyst stance — Piper Sandler reaffirmed an Overweight rating, which is supportive but not uncommon after mixed news; keep an eye on analyst commentary around upcoming data readouts. Piper Sandler Reaffirms Overweight Rating for CRISPR Therapeutics (NASDAQ:CRSP)
• Neutral Sentiment: Short‑interest data appear inconsistent — Recent reports show zero shares and NaN changes, suggesting a data error or reporting lag; this is not currently providing a clear signal on positioning. (Data entries: 3/19–3/20)
• Negative Sentiment: Pipeline uncertainty and timing risk — Coverage notes that while CASGEVY sales are encouraging, several pipeline candidates are early‑stage and investors will wait for additional clinical readouts over the next 12 months before revising convictions. CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty
• Negative Sentiment: Recent share weakness — Multiple market summaries reported multi‑day declines (mid‑ to late‑March), reflecting investor caution despite positive commercial and financing headlines; short‑term price action likely driven by sentiment and upcoming catalysts. CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market Zacks: CRSP Registers a Bigger Fall Than the Market

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Citizens Jmp decreased their price objective on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a report on Friday, January 30th. Citigroup reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, February 16th. Evercore reaffirmed an “outperform” rating and set a $74.00 price target on shares of CRISPR Therapeutics in a research note on Friday, February 13th. Needham & Company LLC lifted their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a report on Friday, February 13th. Finally, Chardan Capital boosted their price objective on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a research report on Saturday, February 14th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $64.53.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 3,450 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $48.26, for a total transaction of $166,497.00. Following the transaction, the general counsel directly owned 91,240 shares in the company, valued at approximately $4,403,242.40. The trade was a 3.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 10,349 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $48.26, for a total transaction of $499,442.74. Following the sale, the chief executive officer directly owned 245,834 shares in the company, valued at $11,863,948.84. This trade represents a 4.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 128,626 shares of company stock worth $7,126,807 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.